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The aromatic diamidine pentamidine has long been used to treat early-stage human African trypanosomiasis
(HAT). Two analogs of pentamidine, DB75 and DB820, have been shown to be more potent and less toxic than
pentamidine in murine models of trypanosomiasis. The diphenyl furan diamidine, DB75, is the active metab-
olite of the prodrug DB289, which is currently in phase III clinical trials as a new orally active candidate drug
to treat first-stage HAT. The new aza analog, DB820, is the active diamidine of the prodrug DB844, currently
undergoing preclinical evaluation as a new candidate to treat HAT of the central nervous system. The exact
mechanisms of antitrypanosomal activity of aromatic dications remain poorly understood, with multiple
mechanisms hypothesized. Pentamidine is known to be actively transported into trypanosomes and binds to
DNA within the nucleus and kinetoplast. A long-hypothesized mechanism of action has been that DNA binding
ultimately leads to interference with DNA-associated enzymes. Both DB75 and DB820 are intensely fluorescent,
which provides an important tool for determining the kinetics of accumulation and intracellular distribution
in trypanosomes. We show in the current study that DB75 and DB820 rapidly accumulate and strongly
concentrate within trypanosomes, with intracellular concentrations over 15,000-fold higher than mouse plasma
concentrations. Both compounds initially accumulate in the DNA-containing nucleus and kinetoplast, but at
later time points, they concentrate in non-DNA-containing cytoplasmic organelles. Analyses of the kinetics of
uptake and intracellular distribution are necessary to begin to define antitrypanosomal mechanisms of action
of DB75, DB820, and other aromatic diamidines.
Human African trypanosomiasis (HAT), a devastating dis-
ease caused by Trypanosoma brucei gambiense and Trypano-
soma brucei rhodesiense, has the potential to affect 60 million
people in sub-Saharan Africa (27). HAT has two stages: an
early stage in which trypanosomes are confined to the blood-
stream and other extracellular fluids and a late stage in which
trypanosomes are able to cross the blood-brain barrier and
invade the central nervous system (CNS). The symptoms of
early-stage HAT are general and include intermittent fever,
malaise, and lymphadenopathy. Infections caused by T. b. gam-
biense and T. b. rhodesiense differ primarily in the manifesta-
tions of the disease. The Gambian form of the disease is a
chronic disease which takes years to progress, while Rhodesian
trypanosomiasis is an acute infection in which the late stage
develops only a few weeks or months following infection (26).
Four drugs are currently available for the treatment of HAT,
all of which are associated with problems, including toxicity,
increasing incidences of treatment failure, and route of admin-
istration (14, 15). Pentamidine and suramin are used for the
treatment of early-stage trypanosomiasis. Pentamidine is used
as a first-line treatment for infections caused by T. b. gambi-
ense, and suramin is used to treat T. b. rhodesiense infections
(11, 15). Melarsoprol and eflornithine are used for CNS or
second-stage infections. Melarsoprol is the drug most often
used to treat second-stage CNS infections caused by both par-
asites. However, melarsoprol is associated with increasing re-
ports of treatment failure (up to 30% in certain areas of central
Africa), and it causes a reactive encephalopathy which can be
fatal in up to 10% of treated patients (15). Eflornithine, also
known as DFMO, is used against only T. b. gambiense CNS
infections (15). Additionally, all of the treatments currently
used must be administered by parenteral injection, which is
difficult in the rural areas affected by trypanosomiasis (14).
Thus, due to the problems associated with current therapy, the
need for new treatments is very pressing.
DB75 [2,5-bis(4-amidinophenyl)furan], also known as fur-
amidine (Fig. 1), is the active metabolite of DB289 [2,5-bis(4-
amidinophenyl)furan-bis-O-methylamidoxime], a prodrug de-
signed to orally treat HAT (T. b. gambiense is the parasite
causing the current epidemic). DB289 recently began phase III
clinical trials in the Democratic Republic of Congo and An-
gola, and a trial has started recruiting patients in southern
Sudan. DB75 is a diamidine analog of pentamidine in which
the alkoxy chain linking the phenyl rings has been replaced
with a furan ring. DB75 has shown excellent in vitro and in vivo
activity in mouse and monkey models of first-stage infection (4,
7, 11, 13). DB820 {6-[5-(4-phenylamidinophenyl)-furanyl-2-yl]-
nicotinamide}, is an aza analog of DB75. DB820 (Fig. 1) is
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more potent than DB75 in the T. b. rhodesiense STIB 900
model of first-stage infection, despite having similar in vitro
activity against that strain (13). DB844, the O-methylami-
doxime prodrug of DB820, has excellent activity in mouse and
monkey models of CNS trypanosomiasis. DB844 is a leading
candidate for the development of a new oral treatment for
CNS trypanosomiasis.
Previous studies have shown that pentamidine is actively
transported into trypanosomes via the P2, HAPT1, and LAPT1
transporters, with very high concentrations accumulating
within trypanosomes (6, 8). Another diamidine, diminazene,
has been shown to be transported into trypanosomes primarily
by the P2 transporter (9). Little is known, however, about the
intracellular distribution of pentamidine, particularly over the
time periods required for this slow-acting compound to kill
trypanosomes. The lack of fluorescence of pentamidine pre-
vents microscopy studies which could determine localization.
The structural modifications of DB75 and DB820 have in-
creased the fluorescence emission of these compounds upon
exposure to UV light. Therefore, we are currently able to
combine studies of accumulation with studies of distribution in
trypanosomes.
The mechanisms of action of DB75 and DB820 as well as
those of many other diamidines are not known, and using
fluorescence microscopy, we can evaluate distributions, to
identify sites of action or potential sites of loss for the com-
pounds in trypanosomes. In this study, T. b. brucei strain S427
was used to investigate the intracellular accumulation and dis-
tribution of the UV fluorescent DB75 and DB820 using high-
pressure liquid chromatography (HPLC) analysis and fluores-
cence microscopy.
This study determined that both DB75 and DB820 achieve
millimolar concentrations in trypanosomes at each respective
time at which the maximum concentration is achieved. DB75
and DB820 also demonstrate a progression in their intracellu-
lar distribution. These compounds first accumulate in the nu-
cleus and kinetoplast, which are the DNA-containing or-
ganelles of trypanosomes. By later time points, both are also
found in organelles that are believed to be the acidocalcisomes
as well as other non-DNA-containing organelles. Accumula-
tion at multiple sites in trypanosomes may be crucial to under-
standing the mechanisms of action of DB75, DB820, and other
diamidines.
MATERIALS AND METHODS
Materials. Complete Baltz’s modified essential medium (CBMEM) was pre-
pared from minimal essential medium supplemented with 100 mM hypoxan-
thine, 2 mM adenosine, 10 mM thymidine, 2 mM sodium pyruvate, 2 mM
L-glutamine, 2-mercaptoethanol, and 10% vol/vol heat-inactivated fetal bovine
serum (Atlanta Biologicals, Atlanta, GA). HPLC-grade water and acetonitrile
were obtained from Fisher Scientific (Pittsburgh, PA). All chemicals were ob-
tained from Sigma-Aldrich Co. (St. Louis, MO) unless otherwise specified.
Parasites. T. b. brucei strain S427 was cultivated in CBMEM medium as
described previously (2). Trypanosomes were maintained in Corning 24-well
plates (Fisher Scientific) and were subpassaged every 3 to 5 days when trypano-
somes reached a density of 105 to 106 trypanosomes per milliliter.
Antitrypanosomal agents. DB75 dihydrochloride salt was synthesized by
Medichem (Chicago, IL) using previously described methods (5, 7). DB820
trihydrochloride salt was synthesized in the laboratory of David Boykin as pre-
viously described (13). For in vitro testing, DB75 and DB820 were prepared as
1-mM stocks in sterile water and, for in vivo testing, the compounds were
prepared in sterile saline (0.9% weight/vol).
In vitro antitrypanosomal activity. In order to determine 50% inhibitory
concentration (IC50) values, S427 trypanosomes (2  103 per ml) were cultured
with serial dilutions of DB75 or DB820 for 70 h using a method described by Raz
et al. (20). Alamar Blue (10% vol/vol) (Biogen International, Camarillo, CA) was
then added, and trypanosomes were further incubated for 2 h. The fluorescence
of Alamar Blue was measured using a PolarStar fluorescence plate reader
(BMG, Durham, NC) using an excitation wavelength of 544 nm and an emission
wavelength of 588 nm. Fluorescence emission at this wavelength is an indication
of cell viability (20). The fluorescence emission derived from each drug concen-
tration was normalized to the fluorescence of the untreated control trypano-
somes. The background fluorescence (determined in wells in which 10% Alamar
Blue was added to CBMEM medium) was subtracted from total fluorescence
values. Dose-response curves were generated from the Alamar Blue fluorescence
shift using Prism (GraphPad Software, San Diego, CA). Experiments were per-
formed in triplicate. IC50 values were determined using the Hill equation.
In vitro accumulation in trypanosomes. To determine in vitro accumulation,
106 trypanosomes were incubated with either 7.5 M DB75 or 7.5 M DB820 for
time periods ranging from 1 to 24 h. At each time point, cells were washed twice
in fresh drug-free medium, lysed, and extracted in 4 volumes of methanol-0.1 N
HCl (8:1 vol/vol). Half of each sample was evaporated in a Zymark (Hopkinton,
MA) TurboVap-LV under nitrogen gas (7 lb/in2) and reconstituted in 50 l of
HPLC solvent A (described in detail in “HPLC analysis of DB75 and DB820”
below). Concentrations were determined as described below.
In vivo antitrypanosomal activity. Dose escalation studies in infected mice
were used to determine in vivo antitrypanosomal activity. All animal experiments
adhered to guidelines outlined by the University of North Carolina—Chapel Hill
Institutional Animal Care and Use Committee. Each test group consisted of six
mice obtained from Charles River (Wilmington, MA). Male Swiss Webster (20
to 30 g) mice were inoculated with 105 S427 trypanosomes intraperitoneally on
day 0. On day 3, mice were treated with a single intravenous (IV) dose (ranging
from 0.63 to 10 mol/kg of body weight) of either compound. The compounds
were administered in 0.9% (wt/vol) saline. The dose volume administered to
each mouse was less than 0.2 ml. Untreated mice were administered the same
saline vehicle. A drop of tail vein blood from each mouse was collected and
examined for trypanosomes using a light microscope (40, magnification) daily
for 2 weeks posttreatment. After that, tail vein blood was examined twice a week
for 60 days. Mice were considered cured when no parasites were found in blood
after the 60-day period. Untreated mice typically died within 5 to 6 days of
infection. The percentage of animals cured in each test group was used to
determine the dose-response curve. Fifty-percent-effective-dose (ED50) values
were calculated in Prism using the Hill equation.
Plasma concentrations of DB75 and DB820 in infected mice. Plasma concen-
trations of DB75 and DB820 were determined in infected animals. In these
experiments, mice were treated with intravenous 7.5 mol/kg of DB75 or DB820
on the third day after infection. Parasitemia was typically about 107 to 108
trypanosomes per milliliter. Animals with lower levels of parasitemia were ex-
cluded from the experiments before treatment.
Plasma samples were prepared as described previously (24), with the following
FIG. 1. Chemical structures of DB75, also known as furamidine,
and DB820, antitrypanosomal diamidine derivatives of pentamidine.
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modifications. Mice were euthanized by CO2 asphyxiation, blood was collected
by cardiac puncture, and the blood was separated into two lithium heparin-
coated BD Microtainer tubes (Fisher Scientific), each with about 400 to 500 l
of blood. One Microtainer tube of the blood was used for determining DB75 and
DB820 plasma concentrations after an IV dose of 7.5 mol/kg through the tail
vein, and the second was used to determine concentrations of DB75 and DB820
in trypanosomes isolated from the infected mice in certain experiments.
Blood was centrifuged at 3,000 rpm (1,500  g) in a Marathon 8K centrifuge
(Fisher Scientific) for 5 min to separate plasma from red blood cells. Plasma was
removed, ensuring that the buffy coat was undisturbed. The buffy coat contains
white blood cells and trypanosomes in infected animals. Approximately 5 to 10
l of plasma was examined under a light microscope (40 to 100 magnifica-
tion) to ensure that it was not contaminated with trypanosomes. DB75 and
DB820 were extracted from plasma in 4 volumes of methanol-0.1 N HCl (8:1
vol/vol), vortexed briefly, and centrifuged at 3,000 rpm (1,500  g) for 5 min. A
total of 100 l of supernatant was removed and evaporated as described previ-
ously (24). The residue was reconstituted in 50 l of HPLC solvent A (for each
respective compound) and transferred to 200 l polypropylene inserts for use in
2.0-ml glass HPLC vials (Agilent Technologies, Palo Alto, CA). Samples were
analyzed by HPLC as described below.
Area under the concentration-time curve (AUC) and half life (t1/2) values
were determined from plasma concentrations using noncompartmental analysis
in WinNonlin 4.1 (Pharsight, Mountain View, CA). The t1/2 value was calculated
from the terminal elimination rate constant calculated between 4 and 24 h. The
AUC was not extrapolated beyond 24 h as concentrations in plasma were often
below the limit of quantification after this time (21).
In vivo accumulation of DB75 and DB820 in trypanosomes. Male Swiss Web-
ster mice were infected with 105 trypanosomes per ml intraperitoneally. On the
third day postinfection, mice were treated with DB75 or DB820 by a single tail
vein injection at a dose level of 7.5 mol/kg. This dose level is curative for both
compounds in this model of infection. At various time points after treatment,
mice were euthanized by CO2 inhalation, and blood was collected by cardiac
puncture. The trypanosomes were collected by centrifuging the blood on a
Percoll (Sigma) gradient as described previously by Grab and Bwayo (12), with
minor modifications to the centrifugation conditions. Briefly, blood was mixed
with an equal volume of 100% Percoll supplemented with 0.25 M sucrose and
0.11 M glucose, in 2.0-ml centrifuge tubes. The blood and Percoll mixture was
centrifuged for 16,100  g for 35 min in an Eppendorf 5415R microcentrifuge
(Fisher Scientific). Trypanosomes were removed from the supernatant, washed
twice, and counted. Compounds were extracted from the trypanosomes using 4
volumes of methanol-0.1 N HCl (8:1 vol/vol). Samples were evaporated under
nitrogen gas (7 lb/in2) in a Zymark TurboVap and resuspended in 100 l of
HPLC solvent A for each respective compound. The average concentration of
DB75 and DB820 in trypanosomes was determined using an estimated cell
volume of 58 m3 (or 58 fl) for the S427 trypanosome (17). The AUC from 0 to
24 h (AUC0—24) and t1/2 values were calculated from trypanosome concentra-
tions using noncompartmental analysis in WinNonlin 4.1. As with plasma, the t1/2
value was calculated from the terminal elimination rate constant between 4
and 24 h.
Intracellular localization of DB75 and DB820 in trypanosomes. To determine
the localization of DB75 and DB820 in trypanosomes, blood smears were made
using a drop of tail blood at each time point after treatment with DB75 or
DB820. Blood smears prepared from untreated mice were also examined. Blood
smears were examined using a Nikon (Garden City, NJ) Microphot FXA with an
objective lens (60 dark medium, 1.4 numerical aperture), a mercury lamp, and
an Optronics (Goleta, CA) DEI 750 charge-coupled device camera. The micro-
scope was equipped with a Nikon UV2A cube that limits excitation wavelengths
to 330 to 380 nm and emission wavelengths to 420 nm.
HPLC analysis of DB75 and DB820. Analytical methods for DB75 were
conducted as described previously (24). Briefly, the solvent system for DB75
analysis consisted of solvent A (15 mM ammonium formate-30 mM formic acid
in 100% HPLC-grade water) and solvent B had the same components in 4:1
acetonitrile–HPLC-grade water. A gradient elution was used to resolve DB75,
with a starting concentration of 88% solvent A-12% solvent B. This gradient
increased linearly to 80% solvent B over 40 min, followed by an 8-min reequili-
bration time to initial solvent conditions.
Analytical methods for DB820 were slightly different. For DB820, solvent A
contained 30 mM ammonium formate-60 mM formic acid in 100% HPLC-grade
water, and solvent B was the same buffer in 4:1 acetonitrile–HPLC-grade water.
A gradient elution was used to resolve the compound, with a starting concen-
tration of 94% solvent A-6% solvent B. This gradient increased linearly to 80%
solvent B over 40 min, followed by reequilibration back to starting concentrations
by 48 min.
An Agilent 1100 series HPLC system equipped with a fluorescence detector
(Agilent Technologies) was used for analytical procedures. DB75 and DB820
were eluted on a 5.0-m Bonus-RP (Agilent Technologies) 2.1-by-150-mm col-
umn with a flow rate of 0.35 ml/min. The column was maintained at 40°C
throughout the analytical method. The injection volume for each sample was 25
l. The excitation and emission wavelengths used for fluorescence detection
were 365 and 462 nm, respectively. Compounds were quantified by comparing to
standards injected during each analytical run. This was used to determine the
concentration of DB75 and DB820 in plasma and in trypanosomes. Concentra-
tions for both compounds were expressed as M and mM for plasma and
trypanosomes, respectively. Concentrations are reported as plus or minus the
standard errors (SEs).
RESULTS
In vitro activity of DB75 and DB820. Both DB75 and DB820
had potent activity against the T. b. brucei S427 strain. The IC50
values were less than 10 nM (Table 1). The related compound
pentamidine was slightly more potent than DB75 and DB820
in vitro with an IC50 value of 1.1 nM.
In vitro accumulation of DB75 and DB820. Trypanosomes
growing in vitro were exposed to DB75 or DB820 at concen-
trations of 7.5 M, approximately 1,000 times the IC50 values.
This concentration is similar to that used in previous studies
with pentamidine (5). Uptake of both DB75 and DB820 in-
creased over time, with millimolar concentrations in trypano-
somes at 24 h (Fig. 2). There appear to be two rises in ac-
cumulation for both compounds; after an initial rise in
concentrations, there is a slight plateau before concentrations
rise again. Although DB75 and its aza analog had similar in
vitro activities, DB75 accumulated to a greater extent in try-
panosomes than DB820 did over the 24 h period. At 24 h,
trypanosomes accumulated DB75 to a concentration of 12.2 
0.8 mM ( SE), or 70.8  4.7 nmol/108 trypanosomes, almost
five times the concentration of DB820 in trypanosomes at that
time (2.6  0.2 mM or 15.0  1.4 nmol/108 trypanosomes).
Thus, DB820 and DB75 were concentrated inside trypano-
somes approximately 400- to 2,000-fold the extracellular incu-
bation concentration at 24 h.
In vivo activity of DB75 and DB820. In vivo efficacy exper-
iments showed that DB75 and DB820 were both very potent in
vivo, with comparable dose-response effects in terms of cure
























a All single doses.
b One animal was excluded from test group due to death on the day following
treatment. The death may have been related to toxicity.
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rates and survival times (Table 1). A single IV dose of either
DB75 or DB820 at 10 mol/kg cured all mice infected with T.
b. brucei S427. Cure was defined as survival with no parasitemia
for 60 days after treatment. ED50 values calculated from the
cure rates were comparable (1.3 mol/kg for DB75 and 1.6
mol/kg for DB820). Pentamidine was less active in vivo, fail-
ing to completely cure all animals at 10 mol/kg IV. The
extrapolated ED50 value for pentamidine was 3.2 mol/kg.
This ED50 value is higher than that previously reported for
pentamidine against the S427 strain, which was between 0.9
and 1.0 mol/kg (or 0.5 to 0.6 mg/kg) (3). However, in this
experiment, mice were infected with trypanosomes and treat-
ment was begun 24 h later. In the experiments reported here,
treatment was begun 3 days postinfection, which is a more
stringent efficacy model. The values reported here are still very
similar to those determined previously.
In vivo accumulation of DB75 and DB820 in trypanosomes
and plasma. Mice infected with T. b. brucei S427 were dosed
with DB75 or DB820 at 7.5 mol/kg IV. Mouse plasma con-
centrations and trypanosome intracellular concentrations for
both compounds were measured over a 24-h period (Fig. 3).
Plasma concentrations of DB75 and DB820 in infected an-
imals. The plasma time concentration profiles for DB75 and
DB820 in infected mice were similar (Fig. 3). The peak plasma
concentration of DB75 in infected mice after IV administra-
tion was 295  93 nM at 15 min posttreatment (Fig. 3A), the
earliest time point measured. The AUC0—24 of DB75 in the
plasma-infected mice was 1.8 M · h. The plasma t1/2 of DB75
was 4.5 h. The peak concentration of DB820 in plasma was
442  145 nM at 15 min posttreatment (Fig. 3B). The AUC
for DB820 in infected plasma was 1.9 M · h, with a t1/2 of
12.4 h. The half lives for DB75 and DB820 in plasma were
calculated between 4 and 24 h.
In vivo accumulation of DB75 and DB820 in trypanosomes.
To determine concentrations of DB75 and DB820 in trypano-
somes, trypanosomes were isolated from blood at multiple
time points after the dosing. Concentrations of DB75 and
DB820 that accumulated in trypanosomes after a single 7.5
mol/kg dose are plotted in Fig. 3. Both compounds were
rapidly taken up and concentrated within trypanosomes, with
0.5 mM intracellular concentrations at 15 min posttreatment,
the earliest time point measured. DB75 peaked in trypano-
somes at a concentration of 0.9  0.2 mM (5.4  1 nmol/108
trypanosomes) at 4 h after administration, approximately 6,000
times the corresponding plasma concentration. The AUC0—24
for DB75 in trypanosomes was approximately 9,400 M · h.
The concentration of DB820 peaked in trypanosomes at 4 h,
with a maximum concentration of 1.8  0.7 mM (9.6  4.3
nmol/108 trypanosomes), which is about 17,000 times the con-
centration in plasma at 4 h. The AUC0—24 for DB820 in try-
panosomes was approximately 17,000 M · h. Both DB75 and
DB820 concentrations in trypanosomes declined over time
with half-lives of 4.9 and 6.4 h, respectively.
FIG. 2. In vitro accumulation of DB75 (■ ) and DB820 (Œ) over
24 h (n  3). Trypanosomes were incubated with 7.5 M of either
compound. Concentrations are presented  SE.
FIG. 3. Concentration of DB75 (A) and DB820 (B) in S427 try-
panosomes and plasma after intravenous administration of 7.5
mol/kg of DB75 or DB820. Experiments were performed with 3 to 6
mice per time point. Concentrations in trypanosomes were determined
based on a volume determination of 58 m3, as determined by Opperdoes
et al. (17). Concentrations are presented  SE.
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Intracellular distribution of DB75 and DB820 in trypano-
somes. Fluorescence microscopy was used to determine the
intracellular distributions of DB75 and DB820 within or-
ganelles of trypanosomes. The fluorescence micrographs (Fig.
4) show that DB75 and DB820 rapidly accumulated in trypano-
somes, concentrating initially in the DNA-containing nucleus
and kinetoplast. At 15 min, when intracellular concentrations
of DB75 and DB820 were approximately 0.5 mM, cell nuclei
showed a bright blue fluorescence. The kinetoplast was also
clearly visible at this early time point, with very intense white-
yellow fluorescence observed (Fig. 4A and F). Nuclear and
kinetoplast fluorescence is apparent at all time points exam-
ined to some degree, but the kinetoplast is not always yellow,
as seen in Fig. 4E. Occasionally, some of the trypanosomes
depicted at 24 h in the micrographs do not have fluorescent
kinetoplasts (Fig. 4J). This appears to be a true phenomenon,
with approximately one-fourth of trypanosomes in multiple
fields showing no kinetoplast fluorescence at 24 h.
Additionally, DB75 appears in unidentified punctate or-
ganelles in the perinuclear region and at the tip of the trypano-
some where the flagellum emerges as a yellow fluorescence
(Fig. 4A). This also occurs with DB820 (Fig. 4F), but not as
much as with DB75. As early as 2 h posttreatment, both com-
pounds are found in organelles believed to be the acidocalci-
somes based on a fluorescence pattern similar to acridine or-
ange in trypanosomes (10). DB75 appears as a yellowish color
in these organelles, while DB820 is a yellowish-orange color.
The DB75- and DB820-accumulating organelles are usually
concentrated at the posterior end of the trypanosome. By 4 h,
the number of yellow fluorescent organelles increases (Fig. 4E
and J) and the number remains that way through 24 h. It is
interesting to note that after 4 h, concentrations of both com-
pounds in trypanosomes begin declining.
DISCUSSION
DB75 and DB820 are potent analogs of pentamidine. Al-
though all three have very similar in vitro activities, in vivo, it
is clear that both DB75 and DB820 have better antitrypano-
somal activity than pentamidine. Even at the highest dose
tested, 20 mol/kg IV of pentamidine, we were unable to cure
the infection in all animals (unpublished results). Additionally,
in the more stringent model of first-stage trypanosomiasis, the
STIB 900 T. b. rhodesiense model, DB820 is the most potent of
these three compounds (13). Both DB75 and DB820 can also
be administered as lipophilic prodrugs, which enables an oral
formulation for the treatment of trypanosomiasis (24). This is
useful, especially for early-stage disease, because it eliminates
the need for parenteral administration. DB289, the prodrug of
DB75, is currently in phase III clinical trials for sleeping sick-
ness. DB844, the prodrug of DB820, is an excellent drug can-
didate for the treatment of CNS trypanosomiasis. DB844 is
able to cure mouse models infected with the chronic GVR35
strain of T. b. brucei after an oral dose of 5  100 mg/kg and
is being investigated in further animal models.
In these studies, T. b. brucei accumulates millimolar concen-
trations of both DB75 and DB820 after both in vitro incubation
and in vivo administration to infected mice (Fig. 2 and 3). The
in vitro concentrations are very similar to concentrations pre-
viously reported by Carter et al. for pentamidine accumulation
(6). They found that pentamidine was accumulated in 108 cells
to a concentration of 1 mM, or 6.05 nmol/108 cells, after a 3-h
in vitro incubation with 1 M pentamidine. This concentration
of pentamidine is approximately 1,000-fold the IC50 value. In
the experiments presented here, trypanosomes were incubated
with 7.5 M of DB75 or DB820, which was approximately
1,000 times the IC50 value for both compounds, and both
accumulated at millimolar levels in vitro over a 24-h period
(Fig. 2). After 4 h, DB75 and DB820 are concentrated in
trypanosomes at almost 200 times the initial concentration,
whereas in Carter’s experiments, pentamidine reaches levels
FIG. 4. Fluorescence micrographs of DB75 and DB820 in trypano-
somes after 7.5 mol/kg intravenous dose of either compound. Panels
A to E show selected time points from DB75-treated mice, while
panels F to J are from DB820-treated mice. In select micrographs, the
nucleus is represented by an arrow, the kinetoplast is depicted by an
asterisk, and the acidocalcisomes are indicated by an arrowhead.
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inside trypanosomes that are approximately 1,000 times the
incubation concentration.
The in vitro accumulation differences of pentamidine and
DB75 and DB820 could be explained by the differing mecha-
nisms for transport into trypanosomes. Pentamidine is trans-
ported into trypanosomes by three transporters, the high- and
low-affinity pentamidine transporters (HAPT1 and LAPT1)
and the P2 transporter (8). The P2 transporter has also been
shown to accumulate DB75 and related diamidines (23), but to
our knowledge, there is no evidence that HAPT1 or LAPT1
can transport DB75 and DB820 into trypanosomes. Therefore,
pentamidine could have accumulated to a greater extent in
trypanosomes due to the multiple routes of drug entry, which
may not be available to DB75 and DB820. A more accurate
comparison for DB75 and DB820 and related diamidines may
be diminazene, which is taken up into trypanosomes almost
exclusively through the P2 transporter (9).
DB75 and DB820 were shown to accumulate in trypano-
somes to concentrations of 1-to-2-mM levels after in vivo treat-
ment (Fig. 3). DB820 has a higher peak concentration and
higher AUC0—24 in trypanosomes than does DB75. The same
holds in plasma; DB820 had a higher peak concentration and
slightly higher AUC0—24 in infected plasma than did DB75.
For most time points, DB820 concentrations in infected
plasma were higher than DB75 plasma concentrations. Plasma
concentrations were also variable, which could be a result of
the infection itself. At the peak concentration in trypanosomes,
the organisms were able to accumulate between 6,000 and
17,000 times the plasma concentrations, which is a very large
concentration factor.
Previously published data (6) suggests that the concentration
of pentamidine in vivo in trypanosomes after a 4 mg/kg dose
administered intraperitoneally to rats is approximately 0.84
mM, which was lower than what was shown here for DB75 and
DB820. A 4-mg/kg dose of pentamidine is equivalent to ap-
proximately 6.75 mol/kg of the isethionate salt, and therefore
the dose of pentamidine administered by Carter et al. was
slightly lower than the doses of DB75 and DB820 administered
in our studies, which was 7.5 mol/kg. Also, the route of
administration used for pentamidine in those experiments was
intraperitoneal injection. Thus, pentamidine required addi-
tional time to enter circulation and distribute into trypano-
somes, and the peak concentration may not have occurred at
their tested time point of 4 h. DB75 and DB820 were admin-
istered by intravenous injection, and do not require extra time
to distribute into circulation. Both the lower dosage and the
different route of administration could explain the lower con-
centration of pentamidine in trypanosomes at 4 h. It is also our
experience that diamidines need to be administered at a much
higher dose intraperitoneally to achieve comparable cure rates
to a dose after intravenous administration. Although the
routes of administration are different in the two studies and
there are other confounding factors, it is clear that trypano-
somes are able to accumulate high concentrations of diami-
dines, which lead to the killing of the organisms.
Diamidines, such as DB75, DB820, and pentamidine, are
able to bind DNA in AT-rich regions of the minor groove (5,
28). In fact, one of the long-hypothesized mechanisms of action
has been binding to DNA and/or interference with DNA-as-
sociated enzymes such as topoisomerase II (21, 22). We ex-
pected to, and did, see accumulation of DB75 and DB820 in
the nucleus and the kinetoplast of trypanosomes, the two
DNA-containing organelles. Although DB75 and DB820 bind
to DNA in both the nucleus and the kinetoplast, it is not known
for certain what effects this may have, or whether accumulation
in one organelle has a greater impact on the death of the
trypanosome. Future studies are planned to investigate whether
different amounts of compound bind to the DNA in these or-
ganelles and how this affects the mechanism of action of the
compounds.
Accumulation in other organelles, such as the organelles
believed to be acidocalcisomes and several unknown perinu-
clear organelles, was unexpected. Accumulation in these or-
ganelles begins about 1 h after treatment is administered. This
organelle accumulation could represent some unknown mech-
anism of action for diamidines, or it could be a source of loss
for the compounds. If these organelles are acidocalcisomes, it
is possible that the diamidines may have some kind of inter-
action with polyphosphates that are sequestered there. Acido-
calcisomes have been postulated to be involved in many pro-
cesses, including pH regulation and osmoregulation within
trypanosomes. Disruption of these processes could potentially
be a mechanism of action. Additionally, these diamidines could
interfere in polyphosphate accumulation and hydrolysis in acido-
calcisomes, a mechanism that has previously been shown to
interfere with trypanosome virulence in animals (16). Support-
ing the idea of accumulation in the acidocalcisomes as a mech-
anism of action of these compounds is the investigation by
Ormerod and Shaw (19). In this study, it was found that stil-
bamidine and hydroxystilbamidine accumulate in “volutin
granules” in trypanosomes. One of these authors also noted a
shift in the fluorescence of hydroxystilbamidine in these gran-
ules, much as is seen here with DB75 and DB820 (18). It is
important to consider that there may be more than one mech-
anism of action for diamidine compounds as a class. Addition-
ally, individual diamidines may display one or more of these
mechanisms of action. In future studies, we hope to examine
the mechanism of action for these and other diamidine com-
pounds.
Another question that arises from the distribution micro-
graphs shown in Fig. 3 is what could explain the shift in fluo-
rescence seen with DB75 and DB820 in the kinetoplast,
acidocalcisomes, and other organelles. DAPI (4,6-diamidino-
2-phenylindole) has been postulated to undergo a red shift in
its fluorescence emission when accumulated in volutin granules
of yeast (1). Volutin granules or the acidocalcisomes in try-
panosomes concentrate polyphosphates and pyrophosphates at
high concentrations, and it has been hypothesized that diami-
dines such as DAPI interact with phosphates, leading to a shift
in the fluorescence emission (25). It appears that the same
phenomenon occurs with DB75 and DB820 in the posterior
organelles, but this does not explain why there is a shift in the
fluorescence emission in the kinetoplast. Potentially, two dif-
ferent mechanisms could cause the shifts in fluorescence in the
organelles. Fluorescence scans of DB75 solutions prepared at
low pH indicated no shift in the fluorescence spectrum to
longer wavelengths; therefore the shift that occurs in these
organelles probably does not occur due to low pH found inside
any of the organelles (J. E. Hall, unpublished data).
The studies described here have opened many opportunities
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for the further study of diamidine compounds. The use of
fluorescence to track the distribution of compounds in try-
panosomes will enable us to examine uptake and intracellular
accumulation as well as distribution and mechanism of action.
When combined with HPLC analysis of concentrations of
drugs in trypanosomes, this is an exciting technique to evaluate
drugs and their antitrypanosomal activity. The studies de-
scribed here will be extended to other compounds in a library
of almost 2,000 structurally diverse diamidines in order to
assess distribution and accumulation over time and how they
relate to activity. Furthermore, using techniques to isolate try-
panosome organelles, it will be possible to evaluate the accu-
mulation of the compounds in each organelle in order to de-
termine how it may relate to mechanism of action.
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